Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Evaluation of Adverse Reactions in Diabetes
NCT02092597Phase 4Completed
- Sponsor
- Charles University
- Start
- Oct 2013
- Primary completion
- Oct 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of exenatide, linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Charles University. Started Oct 2013; status: completed.
02
Drugs
exenatidelinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02092597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092597.